Longeveron Inc. 8-K

What Happened Longeveron announced on July 6, 2026 that CFO Lisa Locklear will step down effective July 10, 2026, and that Marie Washburn will join the executive team as Senior Vice President and Chief Financial Officer effective July 13, 2026. Ms. Washburn has served as Longeveron’s Vice President and Corporate Controller since November 2025 and has over 20 years of finance experience in biotech. Separately, the Board appointed Dr. Arjun “JJ” Desai as a Class III director on July 2, 2026. At the company’s July 1, 2026 annual meeting, shareholders approved an amendment to the Certificate of Incorporation to increase authorized Class A common stock to 175,000,000 shares; the Certificate of Amendment was filed and became effective July 1, 2026.

Key Details

• Marie Washburn appointment effective July 13, 2026; base salary $340,000/year.
• Performance incentive: eligible for annual cash incentive with a target equal to 45% of base salary; awarded 130,000 time‑based restricted stock units upon becoming CFO.
• Lisa Locklear notified the company on June 1, 2026 and will step down as CFO effective July 10, 2026.
• Dr. Arjun “JJ” Desai appointed July 2, 2026 as Class III director; will receive standard, pro‑rated board compensation and an indemnification agreement.

Why It Matters Leadership changes at the CFO level affect financial oversight and investor relations; the company has named an internal finance leader with extensive biotech experience and set clear compensation and equity grant terms. The approved increase in authorized Class A shares gives the company capacity to issue more shares in the future (for financing, equity awards, or other corporate purposes), which investors should note as it may enable future dilution depending on how shares are used. The new board appointment fills a vacancy and maintains governance continuity.